Clinical Trials Browser

Pancreatic Neoplasms × anlotinib × Clear all

NCT06662006 2026-02-06

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06767813 2025-09-19

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05493995 2024-05-09

PAAG

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Phase 1 Unknown

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma